Previous studies have found less than 40% of patients with stable chest pain undergoing invasive coronary angiography are found to have obstructive coronary artery disease. Recent randomized clinical ...

Automated external defibrillators (AEDs) are a common resource in public buildings, yet a new analysis reveals that they are rarely used to help resuscitate people suffering cardiac arrest. Research, ...

Consuming more than 7 grams (>1/2 tablespoon) of olive oil per day is associated with lower risk of cardiovascular disease mortality, cancer mortality, neurodegenerative disease mortality and ...

In this episode, Barbara Srichai-Parsia, MD, FACC, Ron Blankstein, MD, FACC and Roosha Parikh, MD, FACC, will focus on the value of fractional flow reserve – computed tomography (FFR-CT) and emerging ...

Previous studies have shown that yoga therapy and lifestyle modifications have improved heart failure patients' quality of life and enhanced their cardiovascular function. A new study, presented at ...

Statin therapy does not exacerbate muscle injury, pain or fatigue in people engaging in moderate-intensity exercise, such as walking, according to a study published today in the Journal of the ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to new research published in JACC and simultaneously presented at AHA 2024. Among the highlights: ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

The U.S. Food and Drug Administration (FDA) announced on April 15 that Abbott/Thoratec Corp. is recalling the Heartmate II and Heartmate 3 Left Ventricular Assist System (LVAS) due to long-term ...